Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes

F. Boccardo, A. Cavo, E. Zanardi, C. Fabbroni, L. Zinoli, A. Di Meglio, E. Arboscello, A. Bellodi, P. Spallarossa, C. Cattrini, C. Messina, A. Rubagotti

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)vi22
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume28
DOIs
Publication statusPublished - Oct 1 2017

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this